Cohan, S.L.; Lucassen, E.B.; Romba, M.C.; Linch, S.N.
Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis. Biomedicines 2019, 7, 18.
https://doi.org/10.3390/biomedicines7010018
AMA Style
Cohan SL, Lucassen EB, Romba MC, Linch SN.
Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis. Biomedicines. 2019; 7(1):18.
https://doi.org/10.3390/biomedicines7010018
Chicago/Turabian Style
Cohan, Stanley L., Elisabeth B. Lucassen, Meghan C. Romba, and Stefanie N. Linch.
2019. "Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis" Biomedicines 7, no. 1: 18.
https://doi.org/10.3390/biomedicines7010018
APA Style
Cohan, S. L., Lucassen, E. B., Romba, M. C., & Linch, S. N.
(2019). Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis. Biomedicines, 7(1), 18.
https://doi.org/10.3390/biomedicines7010018